Gene and prognostic value of N6-methyladenosine (m6A) modification regulatory factors in lung adenocarcinoma.

Abstract

Lung cancer is the leading cause of death worldwide, and its incidence continues to increase. The treatment of lung cancer is related to the subtypes and stages of cancer, but the therapeutic effect is still unsatisfactory. We found that 10 of the 13 genes were differentially expressed in lung cancer, YTHDF1, RBM15, HNRNPC, KIAA1429, METTL3 and YTHDF2 are high expression while METTL14, ZC3H13, FTO and WTAP are low expression. HNRNPC and METTL3 genes were associated with the risk and prognosis of LUAD and could regard as biomarkers for early diagnosis and treatment, which provides a theoretical basis for LUAD.

• Authors: Di Zhang, DanDan Zhang, Chen Wang, XiaoLi Yang, RongQiang Zhang, Qiang Li, YongMin Xiong
• Journal: European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) (Eur J Cancer Prev) Vol. 31 Issue 4 Pg. 354-362 (07 01 2022) ISSN: 1473-5709 [Electronic] England
• PMID: 34519693 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Chemical References

• N-methyladenosine
• Alpha-Ketoglutarate-Dependent Dioxygenase FTO
• FTO protein, human
• Methyltransferases
• METTL3 protein, human
• Adenosine

Topics

• Adenocarcinoma of Lung (diagnosis, genetics, pathology)
• Adenosine (analogs & derivatives, genetics)
• Alpha-Ketoglutarate-Dependent Dioxygenase FTO (genetics, metabolism)
• Humans
• Lung Neoplasms (diagnosis, genetics)
• Methyltransferases (genetics, metabolism)
• Prognosis